Pages that link to "Q38227648"

The following pages link to The potential for renoprotection with incretin-based drugs (Q38227648):

Displaying 31 items.

• Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data? (Q26777994) (← links)
• Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failure (Q26829634) (← links)
• Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. (Q30374407) (← links)
• Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase-4 inhibitors (Q31036099) (← links)
• Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®) (Q35330816) (← links)
• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (Q36050559) (← links)
• Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study (Q36429742) (← links)
• Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials (Q37696496) (← links)
• Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes (Q38261573) (← links)
• Implications of incretin-based therapies on cardiovascular disease. (Q38264374) (← links)
• Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications (Q38315999) (← links)
• The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class? (Q38527885) (← links)
• The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. (Q38826073) (← links)
• Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury (Q38912532) (← links)
• Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis (Q39001492) (← links)
• Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment (Q39112475) (← links)
• Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes (Q42876331) (← links)
• Second-Line Agents for the Treatment of Type 2 Diabetes and Prevention of CKD. (Q43540210) (← links)
• Diabetic kidney disease. (Q43721013) (← links)
• Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study. (Q48108721) (← links)
• Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice (Q51285414) (← links)
• Glucagon-Like Peptide-1 Mediates the Protective Effect of the Dipeptidyl Peptidase IV Inhibitor on Renal Fibrosis via Reducing the Phenotypic Conversion of Renal Microvascular Cells in Monocrotaline-Treated Rats. (Q52614385) (← links)
• [Diabetic kidney disease - Update 2016]. (Q53620509) (← links)
• Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin. (Q53675099) (← links)
• Incretin-based drugs and renoprotection—is hyperfiltration key? (Q64355407) (← links)
• Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport (Q88652242) (← links)
• Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial (Q89128962) (← links)
• Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial (Q92995741) (← links)
• The authors reply: (Q95618789) (← links)
• Renoprotective Effect of a Dipeptidyl Peptidase-4 Inhibitor on Aging Mice (Q96136872) (← links)
• Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases (Q99571209) (← links)